[1] PEARCE H,CROFT W,NICOL SM,et al .Tissue-resident memory T cells in pancreatic ductal adenocarcinoma coexpress PD-1 and TIGIT and functional inhibition is reversible by dual antibody blockade［J］.Cancer Immunol Res,2023,11(4):435-449.
[2] TICHET M,WULLSCHLEGER S,CHRYPLEWICZ A,et al.Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages［J］.Immunity,2023,56(1):162-179.
[3] ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death［J］.EMBO J,1992,11:3887-3895.
[4] SUH WK,TAFURI A,BERG-BROWN NN,et al.The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28［J］.J Immunol,2004,172:5917-5923.
[5] KEIR ME,BUTTE MJ,FREEMAN GJ,et al.PD-1 and its ligands in tolerance and immunity［J］.Annu Rev Immunol,2008,26:677-704.
[6] JIANG X,WANG J,DENG X,et al.Role of the tumor microenvironment in PDL1/PD-1-mediated tumor immune escape［J］.Mol Cancer,2019,18(1):10.
[7] ZHANG X,SCHWARTZ JC,GUO X,et al.Structural and functional analysis of the costimulatory receptor programmed death-1［J］.Immunity,2004,20(3):337-347.
[8] HOFMEYER KA,JEON H,ZANG X.The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion［J］.J Biomed Biotechnol,2011,2011:451694.
[9] PATSOUKIS N,BROWN J,PETKOVA V,et al.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation［J］.Sci Signal,2012,5(230):ra46.
[10] NICHOLAS KJ,ZERN EK,BARNETT L,et al.B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade［J］.PLoS One,2013,8(12):e84185.
[11] KATAOKA K,SHIRAISHI Y,TAKEDA Y,et al.Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers［J］.Nature,2016,534:402-406.
[12] SKOULIDIS F,BYERS LA,DIAO L,et al.Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology,immune profiles,and therapeutic vulnerabilities［J］.Cancer Discov,2015,5:860-877.
[13] LASTWIKA KJ,WILSON W,LI QK,et al.Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer［J］.Cancer Res,2016,76:227-238.
[14] RIBAS A.Adaptive immune resistance:how cancer protects from immune attack［J］.Cancer Discov,2015,5:915-919.
[15] OKIYAMA N,KATZ SI.Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes［J］.J Autoimmun,2014,53:1-9.
[16] SPRANGER S,KOBLISH HK,HORTON B,et al.Mechanism of tumor rejection with doublets of CTLA-4,PD-1/PD-L1,or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment［J］.J Immunother Cancer,2014,2:3.
[17] GERSHON RK,KONDO K.Cell interactions in the induction of tolerance:the role of thymic lymphocytes［J］.Immunology,1970,18:723.
[18] SAKAGUCHI S,SAKAGUCHI N,ASANO M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases［J］.J Immunol,1995,155:1151-1164.
[19] GIANCHECCHI E,FIERABRACCI A.Inhibitory receptors and pathways of lymphocytes:the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression［J］.Front Immunol,2018,9:2374.
[20] BOYMAN O,SPRENT J.The role of interleukin-2 during homeostasis and activation of the immune system［J］.Nat Rev Immunol,2012,12(3):180-190.
[21] MALCHOW S,LEVENTHAL DS,NISHI S,et al.Aire-dependent thymic development of tumor-associated regulatory T cells［J］.Science,2013,339(6124):1219-1224.
[22] SAKAGUCHI S,WING K,ONISHI Y,et al.Regulatory T cells:how do they suppress immune responses［J］ Int Immunol,2009,21:1105-1111.
[23] VON BOEHMER H,DANIEL C.Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer［J］.Nat Rev Drug Discov,2013,12:51-63.
[24] CHAUDHARY B,ELKORD E.Regulatory T cells in the tumor microenvironment and cancer progression:role and therapeutic targeting［J］.Vaccines,2016,4:1-25.
[25] WARD ST,LI KK,HEPBURN E,et al.The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer［J］.Br J Cancer,2015,112:319-328.
[26] LIU C,WORKMAN CJ,VIGNALI DA.Targeting regulatory T cells in tumors［J］.FEBS J,2016,283:2731-2748.
[27]DUHEN R,FESNEAU O,SAMSON KA,et al.PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors［J］.J Clin Investig,2022,132:e156821.
[28] SIMPSON TR,LI F,MONTALVO-ORTIZ W,et al.Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma［J］.J Exp Med,2013,210:1695-710.
[29] AKEUS P,LANGENES V,KRISTENSEN J,et al.Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors［J］.Eur J Immunol,2015,45:1654-1666.
[30] LEE Y,AWASTHI A,YOSEF N,et al.Induction andmolecular signature of pathogenic TH17 cells［J］.Nat Immunol,2012,13:991-999.
[31] GU C,WU L,LI X.IL-17 family:cytokines,receptors and signaling［J］.Cytokine,2013,64:477-485.
[32] MURUGAIYAN G,SAHA B.Protumor vs antitumor functions of IL-17［J］.J Immunol,2009,183:4169-4175.
[33] MARTIN-OROZCO N,MURANSKI P,CHUNG Y,et al.T helper 17 cells promote cytotoxic T cell activation in tumor immunity［J］.Immunity,2009,31:787-798.
[34] ANKATHATTI MUNEGOWDA M,DENG Y,MULLIGAN SJ,et al.Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity［J］.Cancer Immunol Immunother,2011,60:1473-1484.
[35] QIAN X,CHEN H,WU X,et al.Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis［J］.Cytokine,2017,89:34-44.
[36] KNOCHELMANN HM,DWYER CJ,BAILEY SR,et al.When worlds collide:Th17 and Treg cells in cancer and autoimmunity［J］.Cell Mol Immunol,2018,15:458-469.
[37] GNERLICH JL,MITCHEM JB,WEIR JS,et al.Induction of Th17 cells in the tumor microenvironment improves overall survival in a murine model of pancreatic cancer［J］.J Immunol,2010,185:4063-4071.
[38] CANTINI G, PISATI F, MASTROPIETRO A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment［J］. Cancer Immunol Immunother,2011,60:1739-1750.
[39] BOUTROS C,TARHINI A,ROUTIER E,et al.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination［J］.Nat Rev Clin Oncol,2016,13:473-486.
[40] MENZIES AM,JOHNSON DB,RAMANUJAM S,et al.Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab［J］.Ann Oncol,2016,28:368-376.
[41] PARK HJ,PARK JS,JEONG YH,et al.PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells［J］.J Immunol,2015,194:5801-5811.
[42] FRANCISCO LM,SALINAS VH,BROWN KE,et al.PD-L1 regulates the development,maintenance,and function of induced regulatory T cells［J］.J Exp Med,2009,206:3015-3029.
[43] KOS K,SALVAGNO C,WELLENSTEIN MD,et al.Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling［J］.Oncoimmunology,2022,11(1):2063225.
[44] HONG G,SUN P,CHUNG C,et al.Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer［J］.J Cancer Res Clin Oncol,2023,149(1):159-171.
[45] MISPELBAUM R,HATTENHAUER ST,HELD SAE,et al.Baseline immune signature score of Tregs×HLA-DR+CD4+ T cells×PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients［J］.Front Immunol,2022,13:1054161.
[46] PALOMERO J,PANISELLO C,LOZANO-RABELLA M,et al.Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer［J］.J Immunother Cancer,2022,10(12):e005443.
[47] BASDEO SA,CLUXTON,DEBORAH,et al.Ex-Th17 (Nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells［J］.J Immunol,2017,198:2249-2259.
[48] ESFAHANI K,MILLER W.Reversal of autoimmune toxicity and loss of tumorresponse by interleukin-17 blockade［J］.N Engl J Med,2017,376:1989-1991.
[49] KRIEG C，NOWICKA M,GUGLIETTA S,et al.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy［J］.Nat Med,2018,24(2):144-153.